Pasar al contenido principal

CARACTERIZACION DE BIOMARCADORES DE DISFUNCION DEL TEJIDO ADIPOSO Y DE ACTIVACIÓN DE MACRÓFAGOS PARA EL DIAGNÓSTICO EL ESTADIAJE DEL HIGADO GRASO NO ALCOHÓLICO ASOCIADO A DM2

PI21/00817

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de Investigación en Salud
Año convocatoria 2021
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION INSTITUTO INV GERMANS TRIAS I PUJOL
Centro realización HOSPITAL GERMANS TRIAS I PUJOL

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

NAD+ Precursors and Intestinal Inflammation, Therapeutic Insights Involving Gut Microbiota

  • Niño-Narvión, Julia|||0000-0001-6514-0731
  • Rojo López, Marina Idalia|||0000-0001-6748-3156
  • Martinez-Santos, Patricia
  • Rossell, Joana|||0000-0003-1500-6379
  • Ruiz-Alcaraz, Antonio J.|||0000-0001-6913-0610
  • Alonso Pedrol, Núria|||0000-0001-9687-8050
  • Ramos-Molina, Bruno|||0000-0001-6804-5449
  • Mauricio, Didac|||0000-0002-2868-0250
  • Julve i Gil, Josep|||0000-0002-6531-2246
The oxidized form of nicotinamide adenine dinucleotide (NAD+) is a critical metabolite for living cells. NAD+ may act either as a cofactor for many cellular reactions as well as a coenzyme for different NAD+-consuming enzymes involved in the physiological homeostasis of different organs and systems. In mammals, NAD+ is synthesized from either tryptophan or other vitamin B3 intermediates that act as NAD+ precursors. Recent research suggests that NAD+ precursors play a crucial role in maintaining the integrity of the gut barrier. Indeed, its deficiency has been associated with enhanced gut inflammation and leakage, and dysbiosis. Conversely, NAD+-increasing therapies may confer protection against intestinal inflammation in experimental conditions and human patients, with accumulating evidence indicating that such favorable effects could be, at least in part, mediated by concomitant changes in the composition of intestinal microbiota. However, the mechanisms by which NAD+-based treatments affect the microbiota are still poorly understood. In this context, we have focused specifically on the impact of NAD+ deficiency on intestinal inflammation and dysbiosis in animal and human models. We have further explored the relationship between NAD+ and improved host intestinal metabolism and immunity and the composition of microbiota in vivo. Overall, this comprehensive review aims to provide a new perspective on the effect of NAD+-increasing strategies on host intestinal physiology.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

The double burden, type 1 diabetes and heart failure-a comprehensive review

  • Julián, María Teresa|||0000-0003-2524-1823
  • Pérez-Montes de Oca, Alejandra|||0000-0001-8807-1935
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Alonso Pedrol, Núria|||0000-0001-9687-8050
Heart failure (HF) is increasing at an alarming rate, primary due to the rising in aging, obesity and diabetes. Notably, individuals with type 1 diabetes (T1D) face a significantly elevated risk of HF, leading to more hospitalizations and increased case fatality rates. Several risk factors contribute to HF in T1D, including poor glycemic control, female gender, smoking, hypertension, elevated BMI, and albuminuria. However, early and intensive glycemic control can mitigate the long-term risk of HF in individuals with T1D. The pathophysiology of diabetes-associated HF is complex and multifactorial, and the underlying mechanisms in T1D remain incompletely elucidated. In terms of treatment, much of the evidence comes from type 2 diabetes (T2D) populations, so applying it to T1D requires caution. Sodium-glucose cotransporter 2 inhibitors have shown benefits in HF outcomes, even in non-diabetic populations. However, most of the information about HF and the evidence from cardiovascular safety trials related to glucose lowering medications refer to T2D. Glycemic control is key, but the link between hypoglycemia and HF hospitalization risk requires further study. Glycemic variability, common in T1D, is an independent HF risk factor. Technological advances offer the potential to improve glycemic control, including glycemic variability, and may play a role in preventing HF. In summary, HF in T1D is a complex challenge with unique dimensions. This review focuses on HF in individuals with T1D, exploring its epidemiology, risk factors, pathophysiology, diagnosis and treatment, which is crucial for developing tailored prevention and management strategies for this population.